Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Julphar
AstraZeneca
Covington
Accenture
Chubb

Generated: July 16, 2019

DrugPatentWatch Database Preview

Patent: 9,862,767

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,862,767
Title:Therapeutic methods using anti-CD200 antibodies
Abstract: The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
Inventor(s): Rother; Russell P. (Oklahoma City, OK), Yan; Yan (Cheshire, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:14/739,862
Patent Claims:see list of patent claims

Details for Patent 9,862,767

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28 ➤ Try a Free Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) ➤ Try a Free Trial RX search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26 ➤ Try a Free Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) ➤ Try a Free Trial RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Try a Free Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
UBS
Julphar
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.